The Future of Allergies: New Treatments to Desensitize Your Immune System

The allergy treatment landscape has fundamentally changed. Rather than simply managing symptoms with antihistamines, modern medicine is now focused on retraining the immune system itself through desensitization therapies. This shift represents one of the most significant advances in immunology in recent decades, offering hope to patients who have lived with severe allergies for years or even their entire lives.

The market for allergy treatments is increasingly moving toward immunotherapies and biologics that address the root cause of allergic reactions rather than just treating the symptoms. These innovative approaches work by gradually introducing controlled amounts of allergens to the body, teaching the immune system to tolerate exposure rather than mount an allergic response.

In March 2025, a major milestone was reached with FDA approval of OMLYCLO (omalizumab-igec), marking the first biosimilar designated interchangeable with XOLAIR for treating IgE-mediated food allergy. This approval expands access to effective allergy treatments and reduces costs for patients and insurance providers.

Oral immunotherapy (OIT) currently stands as the only FDA-approved immunotherapy for peanut allergies. However, patients should be aware that Palforzia, the leading OIT treatment, will be discontinued on July 31, 2026, creating urgent demand for alternative immunotherapy options. On the emergency care front, Anaphylm is poised to become the first oral epinephrine formulation for severe allergic reactions and anaphylaxis in patients weighing 30 kg or more, pending FDA approval.

DBV Technologies' Viaskin Peanut represents a revolutionary approach to allergy treatment through epicutaneous immunotherapy (EPIT). This wearable patch delivers small amounts of peanut protein directly through the skin to promote desensitization. The therapy has earned both Fast Track and Breakthrough Therapy designations from the FDA, signaling its potential to address a critical medical need. Currently in Phase III trials with children aged 4-7, DBV Technologies expects to release top-line results from the VITESSE trial in Q4 2025. The beauty of the patch approach lies in its reduced invasiveness compared to oral immunotherapy, potentially lowering the risk of severe allergic reactions while still building tolerance.

Aravax's PVX108 takes a different approach by using engineered peptides to retrain the immune system. Rather than directly introducing allergens, this advanced immunotherapy targets T cells to potentially reverse allergic responses selectively. Currently in Phase II trials for children and adolescents with peanut allergies, PVX108 represents a cutting-edge immunological strategy that could offer more precise immune system modification.

Novartis' Remibrutinib offers yet another innovative mechanism as a highly selective oral Bruton's Tyrosine Kinase (BTK) inhibitor. This medication, presently in Phase II clinical trials for adults with peanut allergies, demonstrates how biotechnology is expanding beyond traditional immunotherapy approaches to address food allergies.

Immunotherapies function on a fundamental principle: controlled, gradual exposure to allergens can train the immune system to tolerate them rather than overreact. Oral and epicutaneous immunotherapy represent the most promising approaches on the horizon. Oral immunotherapy (OIT) involves consuming gradually increasing amounts of the allergen under medical supervision. Sublingual immunotherapy (SLIT) uses drops placed under the tongue. Epicutaneous immunotherapy (EPIT) uses wearable patches to deliver allergens through the skin.

The key advantage of these approaches, particularly EPIT delivered via patches, is that they offer a less invasive alternative to oral routes while potentially reducing the risk of severe allergic reactions during the desensitization process. Research is showing particularly encouraging results when these treatments are started early in childhood, suggesting that early intervention could reshape immune responses and significantly improve long-term quality of life.

The elimination of Palforzia from the market underscores both the challenge and the opportunity in the allergy treatment space. While losing an FDA-approved immunotherapy option is disappointing, it also drives investment in developing better alternatives. The emerging treatment landscape holds multiple therapeutic options, including Viaskin, PVX108, Remibrutinib, and SLIT tablets from ALK-Abello, among others.

For patients managing daily allergy symptoms, non-drowsy antihistamines like loratadine (Claritin), fexofenadine (Allegra), and levocetirizine (Xyzal) remain important tools for symptom management. However, these medications address only the symptoms, not the underlying condition. The new immunotherapies represent a fundamentally different approach—potentially offering long-term or permanent relief by retraining the immune system itself. As more treatments move through clinical trials toward FDA approval, patients can expect increasingly personalized options tailored to their specific allergies, age groups, and medical needs.